Well-differentiated neuroendocrine tumors (NET) are usually slow-growing cancers even when they exhibit local invasion or metastases. Surgery is curative in a minority of patients and systemic chemotherapy is minimally effective. Important cellular processes involved in the pathogenesis of NET have now been identified. In this Review, Reidy et al. discuss the data regarding therapies currently used for treating well-differentiated NETs and the strategies being used in clinical trials.
- Diane L Reidy
- Laura H Tang
- Leonard B Saltz
